Research letterTofacitinib therapy for alopecia areata is not associated with adverse events during COVID-19 infection
Key words
alopecia areata
COVID-19 infection
JAK inhibitor
SARS-CoV-2
tofacitinib
Cited by (0)
Funding sources: None.
IRB approval status: Reviewed and approved by Columbia University’s Human Research Protection Office IRB (protocol # IRB-AAAT5890).
© 2022 by the American Academy of Dermatology, Inc.